Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LBS-007 |
Synonyms | |
Therapy Description |
LBS-007 inhibits the kinase activity of CDC7, potentially resulting in increased tumor cell apoptosis (Blood (2023) 142 (Supplement 1): 1423). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LBS-007 | LBS 007|LBS007|Granaticin B | CDC7 Inhibitor 4 | LBS-007 inhibits the kinase activity of CDC7, potentially resulting in increased tumor cell apoptosis (Blood (2023) 142 (Supplement 1): 1423). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05756322 | Phase Ib/II | LBS-007 | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Recruiting | USA | AUS | 1 |